NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (''Corcept'' or the ''Company'') (CORT). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 25, 2019, Southern Investigative Reporting Foundation (''SIRF'') published a report alleging that Corcept paid doctors to prescribe its drug Korlym for off-label uses.
Following publication of the SIRF report, Corcept's stock price fell $1.52 per share, or more than 11%, to close at $12.29 per share on January 25, 2019.
On this news, Corcept's stock price fell $1.15 per share, or more than 10%, to close at $10.03 per share on February 1, 2019.
On February 5, 2019, Blue Orca Capital published a report alleging that Corcept's ''sole specialty pharmacy and exclusive distributor is an undisclosed related party'' and that the relationship ''creates a material risk that the Company is using its captured pharmacy to boost sales, hide losses, or engage in other financial shenanigans.''
SOURCE: Pomerantz LLP
View source version on accesswire.com: